SPY299.08+3.64 1.23%
DIA250.25+5.37 2.19%
IXIC9,340.22+15.63 0.17%

Chardan Capital Maintains Buy on Passage Bio, Raises Price Target to $32.5

Chardan Capital maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $30 to $32.5.

Benzinga · 05/11/2020 14:47

Chardan Capital maintains Passage Bio (NASDAQ:PASG) with a Buy and raises the price target from $30 to $32.5.